Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 18, 2018 - Issue 4
Submit an article Journal homepage
912
Views
6
CrossRef citations to date
0
Altmetric
Perspective

Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs

George DranitsarisAugmentium Pharma Consulting Inc., Toronto, CanadaCorrespondence[email protected]
View further author information
,
Xiaofu ZhuCross Cancer Institute, Edmonton, CanadaView further author information
,
Georges AdunlinSchool of Pharmacy, Samford University, Birmingham, AL, USAView further author information
&
Mark D VincentLondon Regional Cancer Program, CanadaView further author information
Pages 351-357 | Received 24 Dec 2017, Accepted 17 Apr 2018, Published online: 25 Apr 2018

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Sabine Vogler, Maximilian Salcher-Konrad & Katharina Habimana. (2023) Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?. Expert Review of Pharmacoeconomics & Outcomes Research 23:8, pages 867-878.
Read now
Julian Perelman, Filipa Duarte-Ramos, António Melo Gouveia, Luis Pinheiro, Francisco Ramos, Sabine Vogler & Céu Mateus. (2023) How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015–2021. Expert Review of Pharmacoeconomics & Outcomes Research 23:1, pages 99-109.
Read now
Taro Munakata, Yutaka Handa, Toru Mizuno, Nobuko Tomiuchi, Michael LoPresti & Junichi Shimizu. (2022) The relationship between cost and the recommendation, refusal, and discontinuation of treatment for chronic myeloid leukemia and multiple myeloma in Japan: a cross-sectional exploratory survey. Journal of Medical Economics 25:1, pages 552-560.
Read now
Sabine Vogler. (2021) Can we achieve affordable cancer medicine prices? Developing a pathway for change. Expert Review of Pharmacoeconomics & Outcomes Research 21:3, pages 321-325.
Read now
Pol Specenier. (2021) Cost-effectiveness of nivolumab in advanced melanoma: a drug review. Expert Review of Pharmacoeconomics & Outcomes Research 21:1, pages 13-28.
Read now
Rita De Santis. (2020) Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy. mAbs 12:1.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.